What are the guidelines for prescribing antidepressant medications?

Guidelines for Antidepressant Medications

Initial Treatment Selection

When prescribing antidepressants for major depressive disorder, select second-generation antidepressants based on their adverse effect profiles, cost, and patient preferences—not on efficacy, as all second-generation antidepressants demonstrate equivalent effectiveness 1.

The most recent American College of Physicians guidelines (2023) provide clear direction: for moderate to severe major depressive disorder, use either cognitive behavioral therapy (CBT) monotherapy OR a second-generation antidepressant as monotherapy for initial treatment 2. Combination therapy with both CBT and antidepressants can also be considered, though this carries a conditional recommendation with lower certainty evidence 2.

Severity-Based Approach

• Mild MDD: Start with CBT monotherapy 2
• Moderate to Severe MDD: Choose either:
  • Second-generation antidepressant monotherapy, OR
  • CBT monotherapy, OR
  • Combination therapy (CBT + antidepressant) 2

Medication Selection Factors

Since efficacy is equivalent across second-generation antidepressants 1, base your choice on:

Adverse Effect Profiles:

• Sexual dysfunction concerns: Choose bupropion (lowest rates) over paroxetine (highest rates) 1
• Insomnia: Consider mirtazapine or trazodone 1
• Weight gain concerns: Avoid mirtazapine and paroxetine; prefer sertraline, trazodone, or venlafaxine 1
• Gastrointestinal sensitivity: Avoid venlafaxine (higher nausea/vomiting) and sertraline (higher diarrhea rates) 1

Special Populations:

• Elderly patients (>65 years): All second-generation antidepressants show equivalent efficacy; no age-based preference exists 1
• Gender: Efficacy is equivalent, though prescribing patterns show paroxetine, venlafaxine, and sertraline more commonly prescribed to females 3
• Comorbidities: Trazodone for insomnia; amitriptyline or nortriptyline for headaches; bupropion for tobacco use disorder 3

Monitoring Requirements

Begin monitoring within 1-2 weeks of initiation 1. This early monitoring is critical for:

• Assessing suicidality risk (highest during first 1-2 months, particularly with SSRIs which increase nonfatal suicide attempt risk) 1
• Detecting emergence of agitation, irritability, or unusual behavioral changes 1
• Evaluating tolerability and early adverse effects
• Ensuring medication adherence

Continue regular monitoring throughout treatment to assess therapeutic response and adverse effects 1.

Treatment Response Timeline

Modify treatment if inadequate response occurs within 6-8 weeks of initiation 1. Note that 38% of patients fail to achieve treatment response and 54% fail to achieve remission during 6-12 weeks of treatment 1.

Second-Step Strategies for Non-Response

For patients with moderate to severe MDD who fail initial antidepressant treatment at adequate doses, choose one of these options 2:

1. Switch to CBT or augment with CBT
2. Switch to a different second-generation antidepressant
3. Augment with a second pharmacologic agent

The 2023 evidence shows these switching and augmentation strategies provide similar symptomatic relief, though certainty of evidence remains low 4, 2.

Treatment Duration

Continue treatment for 4-9 months after achieving satisfactory response in first-episode MDD 1. This continuation phase prevents relapse (return of symptoms during the same episode).

For patients with ≥2 prior depressive episodes, extend treatment duration beyond 9 months 1. This maintenance phase prevents recurrence (new distinct episodes).

Critical Caveat on Discontinuation

Discontinuing antidepressants increases relapse/recurrence risk compared to continued use 5. When discontinuing:

• Taper gradually (never abrupt cessation)
• Provide concurrent CBT during tapering to reduce relapse risk 5

Common Adverse Effects to Anticipate

The most frequently reported adverse effects across second-generation antidepressants include 1:

• Constipation
• Diarrhea
• Dizziness
• Headache
• Insomnia
• Nausea (most common reason for discontinuation)
• Sexual dysfunction
• Somnolence

Serious Adverse Effects Requiring Vigilance

• Suicidality: SSRIs increase nonfatal suicide attempt risk (OR 1.57-2.25) 1
• Seizures: Potentially increased with bupropion 1
• Cardiovascular events: Potentially increased with venlafaxine 1
• Hepatotoxicity: Potentially increased with nefazodone 1
• Hyponatremia, serotonin syndrome: Rare but serious complications 1

Key Clinical Pitfalls

1. Assuming efficacy differences exist: All second-generation antidepressants demonstrate equivalent efficacy—do not switch medications based on presumed superior effectiveness 1

2. Delaying monitoring: Early monitoring (1-2 weeks) is mandatory, not optional, given suicide risk 1

3. Premature treatment changes: Allow full 6-8 weeks before declaring treatment failure 1

4. Inadequate continuation treatment: Stopping at symptom resolution without 4-9 month continuation invites relapse 1

5. Abrupt discontinuation: Always taper gradually and consider concurrent CBT 5